Monopar Therapeutics (MNPR) Competitors $44.21 +5.37 (+13.83%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$44.18 -0.03 (-0.07%) As of 09/5/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. AMLX, AKBA, AVXL, IMNM, IOVA, TSHA, NAGE, AVBP, DAWN, and DNTHShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Amylyx Pharmaceuticals (AMLX), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Immunome (IMNM), Iovance Biotherapeutics (IOVA), Taysha Gene Therapies (TSHA), Niagen Bioscience (NAGE), ArriVent BioPharma (AVBP), Day One Biopharmaceuticals (DAWN), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Its Competitors Amylyx Pharmaceuticals Akebia Therapeutics Anavex Life Sciences Immunome Iovance Biotherapeutics Taysha Gene Therapies Niagen Bioscience ArriVent BioPharma Day One Biopharmaceuticals Dianthus Therapeutics Amylyx Pharmaceuticals (NASDAQ:AMLX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Do insiders and institutionals hold more shares of AMLX or MNPR? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor AMLX or MNPR? In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Monopar Therapeutics. MarketBeat recorded 14 mentions for Amylyx Pharmaceuticals and 10 mentions for Monopar Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 1.08 beat Monopar Therapeutics' score of 0.69 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AMLX or MNPR? Amylyx Pharmaceuticals currently has a consensus target price of $12.25, suggesting a potential upside of 20.10%. Monopar Therapeutics has a consensus target price of $69.57, suggesting a potential upside of 57.37%. Given Monopar Therapeutics' higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, AMLX or MNPR? Amylyx Pharmaceuticals has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Is AMLX or MNPR more profitable? Monopar Therapeutics' return on equity of -41.76% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -82.48% -70.15% Monopar Therapeutics N/A -41.76%-39.49% Which has stronger valuation & earnings, AMLX or MNPR? Monopar Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M10.41-$301.74M-$2.50-4.08Monopar TherapeuticsN/AN/A-$15.59M-$3.33-13.28 SummaryAmylyx Pharmaceuticals beats Monopar Therapeutics on 8 of the 14 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$239.64M$3.13B$5.81B$9.92BDividend YieldN/A2.28%6.71%4.52%P/E Ratio-13.2821.1076.0226.12Price / SalesN/A283.48477.0086.71Price / CashN/A44.9736.9659.04Price / Book4.909.8711.456.09Net Income-$15.59M-$53.42M$3.29B$266.51M7 Day Performance29.46%2.93%1.22%0.45%1 Month Performance8.76%9.85%7.89%4.58%1 Year Performance1,749.79%15.74%62.81%26.06% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics3.2664 of 5 stars$44.21+13.8%$69.57+57.4%+1,726.9%$239.64MN/A-13.2810News CoverageAnalyst ForecastAMLXAmylyx Pharmaceuticals2.806 of 5 stars$9.38-0.4%$12.25+30.6%+363.6%$836.39M$87.37M-3.75200News CoveragePositive NewsAKBAAkebia Therapeutics3.7157 of 5 stars$3.14+0.3%$6.75+115.0%+114.5%$832.55M$160.18M-18.47430Analyst UpgradeAVXLAnavex Life Sciences3.8734 of 5 stars$9.64+4.6%$44.00+356.4%+69.1%$828.02MN/A-16.9140Positive NewsIMNMImmunome2.3211 of 5 stars$9.51-3.9%$22.50+136.6%-26.0%$827.80M$9.04M-3.0940News CoverageAnalyst ForecastGap UpIOVAIovance Biotherapeutics4.1761 of 5 stars$2.23flat$11.90+433.6%-76.2%$806.93M$164.07M-1.81500Positive NewsTSHATaysha Gene Therapies2.3771 of 5 stars$2.92+3.2%$8.29+183.8%+59.2%$796.56M$8.33M-8.59180News CoverageNAGENiagen Bioscience2.4201 of 5 stars$9.90+0.8%$13.42+35.6%N/A$789.55M$99.60M47.15120AVBPArriVent BioPharma2.1 of 5 stars$19.12-0.5%$39.14+104.7%-24.1%$775.68MN/A-4.7640Positive NewsDAWNDay One Biopharmaceuticals2.5629 of 5 stars$7.51-1.1%$25.29+236.7%-47.9%$769.26M$131.16M-7.9160News CoveragePositive NewsDNTHDianthus Therapeutics2.2029 of 5 stars$23.57-5.0%$54.00+129.1%-5.3%$758.68M$6.24M-7.2580News CoveragePositive News Related Companies and Tools Related Companies Amylyx Pharmaceuticals Alternatives Akebia Therapeutics Alternatives Anavex Life Sciences Alternatives Immunome Alternatives Iovance Biotherapeutics Alternatives Taysha Gene Therapies Alternatives Niagen Bioscience Alternatives ArriVent BioPharma Alternatives Day One Biopharmaceuticals Alternatives Dianthus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredOdd “310F trade” doubles investor’s money in just 3 days?Have you heard of 310F? This unusual trade setup has quietly delivered one of the most consistent profit st...Eagle Publishing | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
